Literature DB >> 11262645

Further delineation of the facial 13q14 deletion syndrome in 13 retinoblastoma patients.

R I Bojinova1, D F Schorderet, M C Addor, A C Gaide, F Thonney, G Pescia, M Nenadov-Beck, A Balmer, F L Munier.   

Abstract

Thirteen years ago, Motegi and colleagues (J Med Genet 1987;24:696-697) summarized the specific facial phenotype of six Japanese retinoblastoma patients with interstitial 13q14 deletions. Among a series of 228 propositi with retinoblastoma referred to the Lausanne Retinoblastoma Clinic for treatment and genetic counseling between 1986 and 1997, 13 (5.7%) were diagnosed with a cytogenetic de-novo 13q14 deletion. We confirm the presence of the reported facial phenotype in our population of Caucasian patients and describe additional clinical traits, thus extending the facial phenotype associated with the 13q14 deletion. Del(13q14) comprises, among others, cranial anomalies, frontal bossing, deeply grooved and long philtrum, depressed and broad nasal bridge, bulbous tip of the nose, thick lower lip, thin upper lip, broad cheeks, and large ears and lobules. Recognition of this particular facial appearance was instrumental in the genetic diagnosis of 13q deletions and in the presymptomatic diagnosis of retinoblastoma in a significant number of our cases. Identification of this phenotype in a retinoblastoma patient allows for efficient diagnosis of recurrence in his progeny and/or sibship, while its ignorance will compromise genetic counseling due to the possible difficulties in detecting large deletions by standard molecular mutation analysis. Recognition of this syndrome in newborns without known familial risk for retinoblastoma is even more important as it is a clear warning sign that indicates immediate ophthalmic examination.

Entities:  

Mesh:

Year:  2001        PMID: 11262645     DOI: 10.1076/opge.22.1.11.2235

Source DB:  PubMed          Journal:  Ophthalmic Genet        ISSN: 1381-6810            Impact factor:   1.803


  6 in total

1.  Genotype-phenotype correlations in patients with retinoblastoma and interstitial 13q deletions.

Authors:  Diana Mitter; Reinhard Ullmann; Artur Muradyan; Ludger Klein-Hitpass; Deniz Kanber; Katrin Ounap; Marc Kaulisch; Dietmar Lohmann
Journal:  Eur J Hum Genet       Date:  2011-04-20       Impact factor: 4.246

2.  Constitutional retinoblastoma gene deletion in Egyptian patients.

Authors:  Amal M Mohammed; Alaa K Kamel; Saida A Hammad; Hanan H Afifi; Zeinab El Sanabary; Mostafa Ezz El Din
Journal:  World J Pediatr       Date:  2009-08-20       Impact factor: 2.764

3.  Retinoblastoma and mental retardation microdeletion syndrome: clinical characterization and molecular dissection using array CGH.

Authors:  R Caselli; C Speciale; C Pescucci; V Uliana; K Sampieri; M Bruttini; I Longo; S De Francesco; T Pramparo; O Zuffardi; R Frezzotti; A Acquaviva; T Hadjistilianou; A Renieri; F Mari
Journal:  J Hum Genet       Date:  2007-05-15       Impact factor: 3.172

4.  Retinoblastoma management in 13q deletion syndrome patients using super-selective chemotherapies and other cancer-directed interventions.

Authors:  Lucy V Cobbs; Jasmine H Francis; Ira J Dunkel; Y Pierre Gobin; Scott E Brodie; David H Abramson
Journal:  Pediatr Blood Cancer       Date:  2020-12-23       Impact factor: 3.838

Review 5.  Genetic Predisposition to Solid Pediatric Cancers.

Authors:  Mario Capasso; Annalaura Montella; Matilde Tirelli; Teresa Maiorino; Sueva Cantalupo; Achille Iolascon
Journal:  Front Oncol       Date:  2020-10-28       Impact factor: 6.244

6.  13q Deletion Syndrome Involving RB1: Characterization of a New Minimal Critical Region for Psychomotor Delay.

Authors:  Flavia Privitera; Arianna Calonaci; Gabriella Doddato; Filomena Tiziana Papa; Margherita Baldassarri; Anna Maria Pinto; Francesca Mari; Ilaria Longo; Mauro Caini; Daniela Galimberti; Theodora Hadjistilianou; Sonia De Francesco; Alessandra Renieri; Francesca Ariani
Journal:  Genes (Basel)       Date:  2021-08-26       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.